This Month in JNM

SPECT vs. PET in graft infection: Burroni and colleagues review the gold standard of scintigraphy with radiolabeled white blood cells in vascular graft infection and the relative merits of PET and PET/CT in this indication.
Page 1227

PET/CT in vascular graft infection: Keidar and colleagues assess the effectiveness of ¹⁸F-FDG PET/CT in the diagnosis of vascular graft–related complications and in differentiation between graft and soft-tissue infection.
Page 1230

PET/CT in salivary cancer: Jeong and colleagues compare the prognostic and treatment-planning abilities of ¹⁸F-FDG PET/CT and contrast-enhanced CT in patients with high-grade salivary gland malignancies.
Page 1237

Novel PET tracer for GIST: Dimitrakopoulou-Strauss and colleagues describe PET studies with a ⁶⁸Ga-bombesin analog and ¹⁸F-FDG in patients with gastrointestinal stromal tumors to investigate the effects of complementary receptor scintigraphy on diagnostic accuracy.
Page 1245

PET/CT in recurrent esophageal cancer: Guo and colleagues report on the diagnostic and prognostic roles of ¹⁸F-FDG PET/CT in patients with suspected recurrence of esophageal squamous cell carcinoma after definitive treatment.
Page 1251

Algorithms not interchangeable: Chen and colleagues provide data on the selection of reconstruction algorithms for ¹³N-NH₃ PET estimation of quantitative myocardial blood flow.
Page 1259

Receptor effect in breast cancer PET: Mavi and colleagues investigate correlations between ¹⁸F-FDG uptake of primary breast cancer lesions and predictive and prognostic factors such as C-erbB-2, estrogen, and progesterone receptor states.
Page 1266

SPECT and rCBF in depression treatment: Kohn and colleagues use ^99mTc-HMPAO SPECT to determine whether reversal of compromised regional cerebral blood flow in patients with major depressive disorder is dependant on the mode of antidepressant treatment.
Page 1273

¹⁸F-MPPF PET for longitudinal studies: Costes and colleagues assess the reliability and reproducibility of binding parameter quantification for this radiolabeled 5-HT_1A receptor antagonist through a test–retest study over a long-term period.
Page 1279

Advances in Alzheimer's assessment: Matsuda provides an educational overview of the role of neuroimaging in Alzheimer's disease, with a special focus on the utility of statistical analyses in brain perfusion SPECT, PET, and MRI techniques.
Page 1289

Monitoring myocardial therapy: Taki and colleagues evaluate ^99mTc-annexin-V uptake in a rat model of ischemia and reperfusion to determine whether postconditioning or ischemic preconditioning suppress myocardial cell damage or apoptosis.
Page 1301

¹⁸F-FDG and mitochondrial membrane potential: Smith and Blaylock report on in vitro research in breast tumor cells to determine how the loss of mitochondrial membrane potential in apoptosis influences ¹⁸F-FDG incorporation.
Page 1308

VEGF tumor imaging: Nagengast and colleagues describe the development of a radiolabeled humanized monoclonal antibody for noninvasive in vivo vascular endothelial growth factor visualization and quantification with ¹¹¹In and ⁸⁹Zr PET.
Page 1313

Lowered σ₁ binding after therapy: van Waarde and colleagues compare early changes in ¹¹C-SA4503 binding and ¹⁸F-FDG uptake in gliomas after chemotherapy to evaluate the potential of a radiolabeled σ₁-ligand for response monitoring.
Page 1320

⁶⁴Cu-bombesin analogs for preclinical PET/CT: Garrison and colleagues report on studies in a mouse model of prostate cancer to determine whether the CB-TE2A chelation system could significantly improve the in vivo stability of ⁶⁴Cu-bombesin analogs.
Page 1327

Novel carrier modules in lymphoma: DeNardo and colleagues characterize the pharmacokinetics of selective high-affinity ligand molecules that show promise as effective radioisotope carriers for molecular-based imaging and treatment of lymphoma.
Page 1338

Imaging of melanoma metastases: Pham and colleagues describe mouse studies with a novel ¹²³I-labeled molecule for SPECT imaging and staging of metastatic dissemination of melanoma tumors and the potential for therapeutic applications.
Page 1348

¹¹¹In-trastuzumab and nuclear targeting: Costantini and colleagues evaluate the cytotoxicity and tumor-targeting properties of the monoclonal antibody trastuzumab modified with peptides harboring nuclear localization sequences and discuss the potential for radioimmunotherapeutic applications.
Page 1357

Whole-body parametric imaging: Gleisner and colleagues detail a method for pharmacokinetic modeling of distributions of ¹¹¹In-labeled monoclonal antibodies on individual pixels of planar scintillation camera images.
Page 1369

Solid-phase ^99mTc preloading: Misra and colleagues introduce a multimeric, small-molecule radiotracer with high affinity to prostate-specific membrane antigen and describe its production through a solid-phase conversion of sodium ^99mTc-pertechnetate to a general-purpose, reactive form.
Page 1379

Chelate stability and ⁶⁴Cu: Eiblmaier and colleagues explore the question of whether ⁶⁴Cu localization to cell nuclei from internalizing, receptor-targeted radiopharmaceuticals is related to chelate stability.
Page 1390

Journal impact factors: Currie and Wheat provide a general description of journal impact factor statistics in peer-reviewed nuclear medicine literature and discuss the implications, advantages, and shortcomings of these increasingly referenced metrics.
Page 1397

ON THE COVER

⁶⁸Ga-BZH₃ may be helpful diagnostically in some patients with gastrointestinal stromal tumor. Here, ¹⁸F-FDG shows hyper metabolic areas in the liver and stomach, CT shows hypodensity in the same areas, bombesin shows enhancement clearly in the liver but slightly in the stomach, and ¹⁸F-FDG–bombesin fusion shows agreement between the tracers in the liver but not in the stomach. Histology revealed stomach tumor and liver metastasis.

See page 1248.